Drugs / CS08399
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07583771 | Jun 2026 → Aug 2029 expected | diffuse large B-cell lymphoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | Chipscreen Biosciences, Ltd. | Regulatory Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors chipscreen.com ↗
Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences", Stock Code: 688321.SH) today announced that it has received approval from the National Medical Products Administration (NMPA) for the Investigational New Drug (IND) application of its Class 1 novel drug, CS08399 tablets, a brain-penetrant PRMT5 inhibitor for the treatment of the treatment of solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | Chipscreen Biosciences, Ltd. | Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors chipscreen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS08399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583771 ↗ |
| Route | Oral | “Oral tablet.” NCT07583771 ↗ |